LMB-100

mesothelin-targeted immunotoxin · Advanced Immune Therapeutics (as investigational agent in trial; sponsor listed as NCI)

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for LMB-100, covering 2019-11-22 to 2024-02-02. Get the full timeline:

Most recent: Clinical Trial Update: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma [Phase 1]